title: Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
abstract: BACKGROUND
  Acute myeloid leukemia (AML) is an immunophenotypically heterogeneous malignant disease, in which CD34 positivity is associated with poor prognosis. CD34+ AML cells are 10-15-fold more resistant to daunorubicin (DNR) than CD34- AML cells. Curcumin is a major component of turmeric that has shown cytotoxic activity in multiple cancers; however, its anti-cancer activity has not been well studied in DNR-insensitive CD34+ AML cells. The aim of this study was to therefore to explore curcumin-induced cytotoxicity in DNR-insensitive CD34+ AML cell lines (KG1a, Kasumi-1), DNR-sensitive U937 AML cells, and primary CD34+ AML bone-marrow-derived cells.
  
  
  METHODS
  Primary human CD34+ cells were isolated from peripheral blood mononuclear cells or bone marrow mononuclear cells using a CD34 MicroBead kit. The growth inhibitory effects of curcumin were evaluated by MTT and colony-formation assays. Cell cycle distribution was examined by propidium iodide (PI) assay. Apoptosis was analyzed by Wright-Giemsa, Hoechst 33342 and Annexin-V/PI staining assays. The change in mitochondrial membrane potential (MMP) was examined by JC-1 staining and flow cytometry. Expression of apoptosis-related proteins was determined by reverse transcription-polymerase chain reaction and Western blotting. Short interfering RNA (siRNA) against Bcl-2 was used in CD34+ KG1a and Kasumi-1 cells incubated with/without DNR.
  
  
  RESULTS
  Curcumin inhibited proliferation and induced apoptosis and G1/S arrest in both DNR-insensitive KG1a, Kasumi-1 and DNR-sensitive U937 cells. Curcumin-induced apoptosis was associated with reduced expression of both Bcl-2 mRNA and protein, subsequent loss of MMP, and activation of caspase-3 followed by PARP degradation. Curcumin synergistically enhanced the cytotoxic effect of DNR in DNR-insensitive KG1a and Kasumi-1 cells, consistent with decreased Bcl-2 expression. Accordingly, siRNA against Bcl-2 increased the susceptibility of KG1a and Kasumi-1 cells to DNR-induced apoptosis. More importantly, curcumin suppressed Bcl-2 expression, selectively inhibited proliferation and synergistically enhanced the cytotoxicity of DNR in primary CD34+ AML cells, while showing limited lethality in normal CD34+ hematopoietic progenitors.
  
  
  CONCLUSIONS
  Curcumin down-regulates Bcl-2 and induces apoptosis in DNR-insensitive CD34+ AML cell lines and primary CD34+ AML cells.
authors: Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, P.R. China.
authors: Jia
authors: J
authors: Rao
authors: Duo-Rong
authors: DR
authors: Xu
authors: Fei-Meng
authors: FM
authors: Zheng
authors: Zi-Jie
authors: ZJ
authors: Long
authors: Sheng-Shan
authors: SS
authors: Huang
authors: Xing
authors: X
authors: Wu
authors: Wei-Hua
authors: WH
authors: Zhou
authors: Ren-Wei
authors: RW
authors: Huang
authors: Quentin
authors: Q
authors: Liu
references: Cancer Lett. 2005 Jun 16;224(1):53-65
references: 15911101
references: Anticancer Res. 2006 Nov-Dec;26(6B):4423-30
references: 17201164
references: Blood. 2001 Jun 1;97(11):3574-80
references: 11369653
references: Cancer Res. 1983 Jul;43(7):3417-21
references: 6850648
references: Clin Cancer Res. 2008 Jul 15;14(14):4491-9
references: 18628464
references: Leuk Res. 2004 Jan;28(1):43-8
references: 14630079
references: Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):120-5
references: 15668484
references: Leukemia. 1995 May;9(5):799-807
references: 7769842
references: Cancer Lett. 2008 Aug 18;267(1):133-64
references: 18462866
references: Cancer Lett. 2008 Jan 18;259(1):111-8
references: 18006147
references: Ann Hematol. 2008 May;87(5):353-60
references: 18228020
references: Haematologica. 2005 Jan;90(1):54-9
references: 15642669
references: Trends Pharmacol Sci. 2009 Feb;30(2):85-94
references: 19110321
references: Biochem Pharmacol. 2008 Dec 1;76(11):1590-611
references: 18775680
references: Int J Cancer. 2009 Oct 15;125(8):1992-3
references: 19618459
references: Cytometry B Clin Cytom. 2003 May;53(1):11-9
references: 12717686
references: Nat Rev Cancer. 2005 Apr;5(4):275-84
references: 15803154
references: Mol Cancer Ther. 2008 Sep;7(9):2609-20
references: 18790744
references: Mol Cancer Ther. 2010 Oct;9(10):2665-75
references: 20937593
references: Cancer Lett. 2008 Oct 8;269(2):199-225
references: 18479807
references: Apoptosis. 2006 Feb;11(2):245-54
references: 16502262
references: Cancer. 2006 Jun 1;106(11):2503-13
references: 16628653
references: Lancet. 2006 Nov 25;368(9550):1894-907
references: 17126723
references: Biochem Pharmacol. 2003 Nov 1;66(9):1779-86
references: 14563488
references: Leuk Lymphoma. 1992 Aug;7(5-6):425-9
references: 1283545
references: Haematologica. 2003 May;88(5):497-508
references: 12745269
references: Br J Haematol. 1990 Nov;76(3):340-7
references: 1702006
references: Leukemia. 1997 Sep;11(9):1523-32
references: 9305608
references: Mol Oncol. 2008 Dec;2(4):317-26
references: 19383353
references: Zhongguo Yao Li Xue Bao. 1980 Dec;1(2):70-6
references: 6461187
references: Assay Drug Dev Technol. 2007 Aug;5(4):567-76
references: 17767425
references: Biochem Pharmacol. 2005 Sep 1;70(5):700-13
references: 16023083
references: Cancer Gene Ther. 2006 Apr;13(4):406-14
references: 16195754
references: Biochem Biophys Res Commun. 2003 Apr 18;303(4):1073-9
references: 12684045
references: Nutr Cancer. 2010;62(6):811-24
references: 20661831
references: BMC Complement Altern Med. 2006 Mar 17;6:10
references: 16545122
references: Cancer Res. 2010 Jan 15;70(2):440-6
references: 20068163
references: Chem Biol Interact. 2009 Oct 7;181(2):263-71
references: 19573523
references: Blood. 1980 Aug;56(2):265-73
references: 6967340
references: Mol Cell Biochem. 2007 Mar;297(1-2):31-9
references: 17096185
references: Blood. 1991 May 1;77(9):2031-6
references: 2018839
references: Pharmacol Rev. 2006 Sep;58(3):621-81
references: 16968952
references: Br J Haematol. 2002 Aug;118(2):521-34
references: 12139741
references: Int J Cancer. 2006 Feb 1;118(3):765-72
references: 16106398
references: Transl Oncol. 2009 Dec;2(4):321-8
references: 19956394
references: Blood. 2005 Aug 15;106(4):1154-63
references: 15870183
references: Leukemia. 2008 Oct;22(10):1899-908
references: 18650843
references: Oncogene. 2004 Apr 12;23(16):2850-60
references: 15077148